Recombinant nonimmunogenic staphylokinase

DRUG2 trials

Sponsors

Supergene, LLC

Conditions

COVID-19Massive Pulmonary Embolism

Phase 2

Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

TerminatedNCT05135546

Supergene, LLCCOVID-19

Start: 2021-12-27End: 2023-05-31Updated: 2023-07-03

Phase 3

Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE

CompletedNCT04688320

Supergene, LLCMassive Pulmonary Embolism

Start: 2020-12-15End: 2023-07-27Updated: 2025-04-02

Related Papers

The Safety of Non‐immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE

Health Science Reports2025-05-013 citations